Cambridge Investment Research Advisors Inc. lifted its position in DexCom, Inc. (NASDAQ:DXCM) by 55.2% during the 2nd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 6,851 shares of the medical device company’s stock after buying an additional 2,436 shares during the period. Cambridge Investment Research Advisors Inc.’s holdings in DexCom were worth $2,777,000 as of its most recent SEC filing.
Other large investors have also recently bought and sold shares of the company. Nisa Investment Advisors LLC boosted its position in shares of DexCom by 54.9% during the second quarter. Nisa Investment Advisors LLC now owns 16,052 shares of the medical device company’s stock valued at $6,507,000 after buying an additional 5,690 shares during the last quarter. Nissay Asset Management Corp Japan ADV boosted its holdings in shares of DexCom by 7.8% during the 2nd quarter. Nissay Asset Management Corp Japan ADV now owns 11,963 shares of the medical device company’s stock valued at $4,850,000 after acquiring an additional 869 shares during the last quarter. NN Investment Partners Holdings N.V. boosted its holdings in shares of DexCom by 6.2% during the 2nd quarter. NN Investment Partners Holdings N.V. now owns 12,746 shares of the medical device company’s stock valued at $5,167,000 after acquiring an additional 747 shares during the last quarter. Dupont Capital Management Corp grew its stake in shares of DexCom by 74.3% in the second quarter. Dupont Capital Management Corp now owns 7,659 shares of the medical device company’s stock worth $3,105,000 after acquiring an additional 3,264 shares during the period. Finally, Covenant Asset Management LLC purchased a new position in shares of DexCom during the second quarter valued at approximately $2,884,000. Hedge funds and other institutional investors own 97.08% of the company’s stock.
A number of brokerages have weighed in on DXCM. Stifel Nicolaus boosted their target price on shares of DexCom from $385.00 to $500.00 and gave the company a “buy” rating in a research note on Wednesday. JPMorgan Chase & Co. increased their target price on DexCom from $360.00 to $450.00 and gave the company an “overweight” rating in a report on Monday, July 27th. Piper Sandler boosted their price target on DexCom from $450.00 to $465.00 and gave the company an “overweight” rating in a research note on Wednesday. Citigroup increased their price objective on shares of DexCom from $440.00 to $485.00 and gave the stock a “buy” rating in a research note on Wednesday. Finally, Robert W. Baird raised their price objective on shares of DexCom from $296.00 to $373.00 and gave the stock an “outperform” rating in a report on Wednesday, April 29th. Seven investment analysts have rated the stock with a hold rating and seventeen have given a buy rating to the stock. DexCom has a consensus rating of “Buy” and a consensus target price of $394.95.
DXCM opened at $435.54 on Friday. The company has a debt-to-equity ratio of 1.28, a quick ratio of 5.41 and a current ratio of 7.58. The stock has a market capitalization of $41.70 billion, a price-to-earnings ratio of 143.74, a PEG ratio of 4.74 and a beta of 0.79. The company has a fifty day moving average of $410.52 and a 200 day moving average of $325.07. DexCom, Inc. has a fifty-two week low of $138.28 and a fifty-two week high of $446.50.
DexCom (NASDAQ:DXCM) last issued its quarterly earnings data on Tuesday, July 28th. The medical device company reported $0.79 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.31 by $0.48. DexCom had a return on equity of 29.01% and a net margin of 11.93%. The firm had revenue of $451.80 million during the quarter, compared to analyst estimates of $415.21 million. During the same quarter last year, the business posted $0.08 earnings per share. The business’s quarterly revenue was up 34.3% compared to the same quarter last year. On average, equities research analysts forecast that DexCom, Inc. will post 2.45 earnings per share for the current year.
In other news, SVP Shelly Ramasamy Selvaraj sold 400 shares of the company’s stock in a transaction dated Friday, July 10th. The shares were sold at an average price of $439.33, for a total transaction of $175,732.00. The sale was disclosed in a legal filing with the SEC, which is available through this link. Also, EVP Steven Robert Pacelli sold 1,531 shares of the stock in a transaction dated Thursday, July 23rd. The shares were sold at an average price of $427.31, for a total transaction of $654,211.61. Following the completion of the transaction, the executive vice president now directly owns 51,482 shares of the company’s stock, valued at approximately $21,998,773.42. The disclosure for this sale can be found here. Insiders have sold a total of 63,293 shares of company stock valued at $24,266,963 over the last quarter. Corporate insiders own 0.69% of the company’s stock.
DexCom Company Profile
DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G6, a CGM system for diabetes management; DexCom G5 mobile CGM system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.
Featured Story: What is a good dividend yield?
Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).
Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.